Dengue is transmitted by the bite of an Aedes mosquito infected with any one of the four dengue viruses. It occurs in tropical and sub-tropical areas of the world. Symptoms appear 3—14 days after the infective bite. Dengue fever is a febrile illness that affects infants, young children and adults.
Symptoms range from a mild fever, to incapacitating high fever, with severe headache, pain behind the eyes, muscle and joint pain, and rash. There are no specific antiviral medicines for dengue. It is important to maintain hydration. Use of acetylsalicylic acid (e.g. aspirin) and non steroidal anti-inflammatory drugs (e.g. Ibuprofen) is not recommended.
Severe dengue (plasma leakage, severe hemorrhages, organ failure) is a potentially lethal complication, affecting both children and adults. early clinical diagnosis and careful clinical management by experienced physicians and nurses increase survival of patients.
TDR related research
TDR supports research on this disease. For more information, visit these research sections:
Critical research findings for dengue – fostering the arbovirus research agenda
New global vector control response at World Health Assembly
TDR publications and articles
Operational Guide: Early Warning and Response System (EWARS) for dengue outbreaks
Technical handbook for dengue surveillance, dengue outbreak prediction/detection and outbreak response
Biosafety for human health and the environment in the context of the potential use of genetically modified mosquitoes (GMMs)